参考文献/References:
［1］ QI H J,LI X X,ZHANG J Y,ZHAO M W.Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients［J］.Int J Ophthalmol,2017，10(1):91-97.
［2］ KIM K L，SEO S，KIM J T,KIM W,YEO Y，et al.SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization［J］.Arterioscler Thromb Vasc Biol,2019,39（10）：2128-2131.
［3］ JUN L I,ZHANG H,SUN P,GU F,LIU Z L.Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients［J］.Int J Ophthalmol,2013,6(2):169-173.
［4］ National Institute for Health and Care Excellence.Age-related macular degeneration:diagnosis and management［EB/OL］.（2018-01-23）.https://www.nice.org.uk/guidance/ng82.
［5］ HUO C D,ZHANG W F,YANG Y，LI Y T.Application of ophthalmic auxiliary examination in age-related macular degeneration［J］.Int Eye Sci,2018,18(1):84-88.
火成栋,张文芳,杨义,李玉婷.眼科辅助检查在年龄相关性黄斑变性中的应用［J］.国际眼科杂志,2018,18(1):84-88.
［6］ ZHANG Y Z,PENG H.Progress in the treatment of dry age-related macular degeneration［J］.Rec Adv Ophthalmol,2017,37(4):379-383.
［7］ VISHWANATHAN R，CHUN G M，JOHNSON E J.A systemat-ic review on zinc for the prevention and treatment of age-related macular degeneration［J］.Invest Ophthalmol Vis Sci，2013，54(6):3985-3998.
［8］ SIN H P，LIU D T，LAM D S.Lifestyle modification，nutritional and vitamins supplements for age-related macular degeneration［J］.Acta Ophthalmol，2012，91(1):6-11.
［9］ GEHRS K M，JACKSON J R，BROWN E N，ALLIKMETS R，HAGEMAN G S.Complement，age-related macular degeneration and a vision of the future［J］.Arch Ophthalmol，2010，128(3):349-358.
［10］ CHEREPANOFF S，MCMEN AMIN P，GILLIES M C，KETTLE E，SAＲKS S H.Bruch’s membrane and choroidal macrophages in early and advanced age-related macular degeneration［J］.Br J Ophthalmol，2010，94(7):918-925.
［11］ SINHA D,VALAPALA M,SHANG P,HOSE S,GREBE R,LUTTY G A,et al.Lysosomes:regulators of autophagy in the retinal pigmented epithelium［J］.Exp Eye Res,2016,144:46-53.
［12］ KARUNADHARMA P P,NORDGAARD C L,OLSEN T W,FER-RINGTON D A.Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration［J］.Invest Ophthalmol Vis Sci,2010,51(11):5470-5479.
［13］ DOU G,SREEKUMAR P G,SPEE C,HE S,RYAN S,KANNAN R,et al.Deficiency of αB crystallin augments ER stress-induced apoptosis by enhancing mitochondrial dysfunction［J］.Free Radical Bio Med,2012,53(5):1111-1122.
［14］ STAELS W,HEREMANS Y,HEIMBERG H,DE LEU N.VEGF-A and blood vessels:a beta cell perspective［J］.Diabetologia,2019,［Epub ahead of print］.
［15］ HAN K Y,CHANG J H,LEE H,AZAR D T.Proangiogenic interactions of vascular endothelial MMP14 with VEGF receptor 1 in VEGFA-mediated corneal angiogenesis［J］.Invest Ophthalmol Vis Sci,2016,57（7）:3313-3322.
［16］ TAH V,ORLANS H O,HYER J,CASSWELL E,DIN N,SRI SHANMUGANATHAN V，et al.Anti-VEGF therapy and the retina:an update［J］.J Ophthalmol,2015,2015:627674.
［17］ SCHMIDT-ERFURTH U,KAISER P K,KOROBELNIK J F,BROWN D M,CHONG V,NGUYEN Q D,et al.Intravitreal aflibercept injection for neovascular age-related macular degeneration:ninety-six-week results of the VIEW studies［J］.Ophthalmology,2014,121:193-201.
［18］ JUN L I,ZHANG H,SUN P,GU F,LIU Z L.Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients［J］.Int J Ophthalmol,2013,6(2):169-173.
［19］ O’DAY R F，PEJNOVIC T M，ISAACS T，MUECKE J S，GLASSON W J，CAMPBELL W G.Australian and new zealand study of photodynamic therapy in choroidal amelanotic melanoma［J］.Retina,2019［Epub ahead of print］.
［20］ IWASE T,UENO Y,RA E,ITO Y,TERASAKI H.Changes in choriocapillaris and retinal morphology after laser photocoagulation by OCT angiography:A case report［J］.Medicine (Baltimore),2018,97(46):e13278.
［21］ SOLEIMANI A,RASTA S H,BANAEI T,ASGHARSHARGHI BONAB A.Effects of laser physical parameters on lesion size in retinal photocoagulation surgery:clinical OCT and experimental Study［J］.J Biomed Phys Eng,2017,7(4):355-364.
［22］ KUBICKA-TRZASKA A,WILA N ′ SKA J.Serum antiretinal antibodies (ARA) in patients with exudative age-related macular degeneration (AMD) treated with transpupillary thermotherapy (TTT) alone and with transpupillary thermotherapy (TTT) combined with injection of triamcinolone acetonide (sTTA) under posterior Tenon’s capsule［J］.Klin Oczna,2011,113:28-33.
［23］ MANAYATH G J,KARANDIKAR S S,NARENDRAN S,KUMARSWAMY K A,SARAVANAN V R,MORRIS RJ,et al.Low fluence photodynamic therapy versus graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy:results from a prospective study［J］.Ophthalmic Surg Lasers Imaging Retina,2017,48(4):334-338.
［24］ ZHANG X.Rencent advance of the study on treatment for age-related macular degeneration［J］.Int J Ophthalmol,2007,7(6):1674-1676.
［25］ ZEEBURG E J T V,MAAIJWEE K J M,MISSOTTEN T O A R,HEIMANN H,MEURS J C V.A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration:results up to 7 years［J］.Am J Ophthalmol,2012,153(1):120-127.
［26］ CARAMOY A,LIAKOPOULOS S,KIRCHHOF B.Recurrence of choroidal neovascular membrane after autologous transplantation of RPE and choroid for neovascular AMD［J］.Acta Ophthalmol,2011,89(8):666-668.
相似文献/References:
[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[5]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[6]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[9]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[10]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[11]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[12]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[13]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[14]魏菁,黄厚斌. 吲哚青绿介导的光栓塞治疗黄斑中心凹下脉络膜新生血管[J].眼科新进展,2014,34(9):842.[doi:10.13389/j.cnki.rao.2014.0232]
[15]于靖,刘晴雨,吴岩.阿司匹林是年龄相关性黄斑变性的危险因素[J].眼科新进展,2014,34(10):901.[doi:10.13389/j.cnki.rao.2014.0249]
[16]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(11):473.[doi:10.13389/j.cnki.rao.2017.0120]
[17]卢悦,蔡玲,朱晨,等.人参皂苷RG3对脉络膜新生血管的抑制作用[J].眼科新进展,2017,37(10):922.[doi:10.13389/j.cnki.rao.2017.0234]
LU Yue,CAI Ling,ZHU Chen,et al.Inhibitory effect of ginsenoside RG3 on choroidal neovascularization[J].Recent Advances in Ophthalmology,2017,37(11):922.[doi:10.13389/j.cnki.rao.2017.0234]
[18]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(11):130.[doi:10.13389/j.cnki.rao.2021.0027]
[19]付燕,张月玲,王丽英,等.湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后[J].眼科新进展,2021,41(3):254.[doi:10.13389/j.cnki.rao.2021.0053]
FU Yan,ZHANG Yueling,WANG Liying,et al.Factors and outcomes associated with failure to anti-VEGF treatment in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(11):254.[doi:10.13389/j.cnki.rao.2021.0053]
[20]胡梦燕,邵毅,裴重刚.年龄相关性黄斑变性患者色素上皮形态与最佳矫正视力的关系研究进展[J].眼科新进展,2021,41(8):797.[doi:10.13389/j.cnki.rao.2021.0167]
HU Mengyan,SHAO Yi,PEI Chonggang.Research progress on the relationship between pigment epithelium morphology and best corrected visual acuity in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(11):797.[doi:10.13389/j.cnki.rao.2021.0167]